Mounjaro®
Starting from £179.99/mo
Start journey Learn moreWegovy begins working from the very first dose, at 0.25 mg — but that starting dose is designed to help your body adjust, not to drive significant weight loss straight away. Most people notice meaningful appetite changes as the dose increases toward 1.0 mg and beyond, with the greatest effect typically seen at the licensed maintenance dose of 2.4 mg over time. Because semaglutide is a prescription-only medicine, a clinical assessment is needed before you can start, a prescriber reviews your full picture and guides the titration schedule that applies to you specifically.
At your door the next working day.
Free, tracked, plain packaging.
BMI isn't the whole story, but it's where clinicians start. Check yours in ten seconds — nothing is stored, nothing is shared.
Ten seconds. Private — nothing is stored or shared.
Your result updates live in the card alongside.
Your result
Your BMI is
—
which is in the healthy weight range
Start journeyBMI doesn't determine eligibility — only a clinician can assess whether treatment is right for you.
The problem
The nume way
clinician review. Free next working day delivery.
How it works
Tell us about your health, history and goals. Free, online, and confidential — no commitment, no waiting room.
Our team reviews your health the same day — never an algorithm, and approves your treatment there and then if eligible.
Order by 12pm, dispatched same day, delivered free the next working day — the nume Promise.
The 0.25 mg first dose exists entirely for your comfort. Semaglutide slows stomach emptying and raises gut-hormone signals involved in appetite, useful effects, but ones that can cause nausea, bloating or indigestion if they hit full-strength from day one. Starting low gives the body a chance to adapt before the dose climbs.
That said, "not working yet" isn't quite right. The medicine is active at 0.25 mg; the gut receptors are responding. What's lower is the magnitude of appetite suppression at that concentration. The full Wegovy dosing schedule describes each step (0.25 mg, 0.5 mg, 1.0 mg, 1.7 mg, 2.4 mg) and most prescribers hold each level for about four weeks before the next increase, provided it's tolerated well.
Some people do notice reduced hunger even in the first two or three weeks. Others feel little change until 0.5 mg or 1.0 mg. Both patterns are common. Neither means the medicine is failing you; individual response to GLP-1 receptor agonists varies, and the titration schedule exists precisely to bring everyone through safely. The Wegovy overview page covers the broader mechanism if you'd like more on how semaglutide works.
For most people, the clearest shift happens around 0.5 mg to 1.0 mg, when appetite reduction becomes harder to ignore. Meals feel smaller, the pull toward snacking fades, and total calorie intake tends to fall, often without conscious effort. That's the GLP-1 effect in practice.
Weight loss at this stage is real but modest. It accumulates meaningfully at the 1.7 mg and 2.4 mg levels, where the medicine is working at full therapeutic strength. The STEP 1 trial, published in the New England Journal of Medicine, recorded around 15% average weight reduction over 68 weeks at 2.4 mg alongside lifestyle changes, a figure that reflects months of treatment at maintenance, not weeks at the starter dose.
If you're partway through the titration and wondering whether progress is on track, the pages on 0.5 mg not feeling effective and 1 mg not working cover what's normal at each step and when it's worth raising the question with your prescriber.
Progress isn't linear, and the experience shifts as the dose climbs. Here's how the stages tend to feel in practice.
0.25 mg: Appetite may feel slightly quieter, but the main job is adjustment. Side effects, if any, are usually at their most noticeable here and tend to settle within a week or two. Many people find it helpful to keep the pen in the fridge door where they'll see it on injection day, routine matters when you're building a weekly habit.
0.5 mg to 1.0 mg: This is typically where hunger patterns shift more clearly. Portion sizes often fall naturally. Weight loss begins to show, though slowly. The 1 mg stage is sometimes where people question whether Wegovy is working, the answer is almost always that the full effect is still building.
1.7 mg to 2.4 mg: The maintenance territory. Appetite suppression is at its strongest, and weight loss tends to be most consistent. NICE's appraisal of semaglutide (TA875) considers the 5% weight-loss threshold at maintenance a useful clinical marker, if that isn't reached after six months at the highest tolerated dose, continuing is reviewed with the prescriber. Questions about 2.4 mg not feeling effective are covered in their own page.
Patience with the timeline matters here. Reaching 2.4 mg typically takes around 16 weeks of dose escalation, and significant weight loss accumulates over months beyond that, not days. The question of how many doses it takes to see meaningful loss gets a thorough answer elsewhere, but the honest short version is: the titration phase is a prerequisite, not a delay.
Some people also reach a dose that is the highest they tolerate well, rather than the highest on the schedule. That is still a valid maintenance dose, and the prescriber's role is to identify where your individual balance of effect and tolerability sits. Comparing your early weeks against trial averages at 2.4 mg isn't a fair test. At what dose Wegovy starts working for weight loss, in the meaningful clinical sense, is a question that really resolves over the full treatment arc.
If you'd like to explore whether Wegovy or another licensed weight-loss treatment might suit your situation, a free consultation with our prescribers is the place to start. There's no obligation, and the clinical review takes place the same day.
The people
Superintendent Pharmacist (GPhC No. 2217101)
Accountable for the safe running of our registered pharmacy, from every dispensing check to every dispatch.
Clinical Lead (GPhC No. 2231744)
Sets our clinical standards and checks everything we publish against current MHRA guidance.
Independent Prescriber (GPhC No. 2084501)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.
Independent Prescriber (GPhC No. 2083426)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.